retatrutide fda Approval 2025–2026: Phase 3 Trials, Timeline & Access fda retatrutide Retatrutide, an experimental

31,35-37 Prospective trials are needed to further explore this potential adverse event and worsened DR, which is the central premise of the ophthalmic FOCUS trial that is expected to release results in 2026

Current understanding is largely based on pharmacovigilance data, clinical trial secondary endpoints, case reports, and small observational studies

Patients were required to have evidence of a GLP-1 RA prescription fill and documented reason for discontinuation from a GLP-1 RA

Although it is important to remember that sometimes these premade meals tend to be high in sodium, so even if they are portion controlled you can end up consuming more sodium that what is recommended as healthy